Market Overview:
The global oritavancin API market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of infectious diseases, rising demand for oritavancin API in research and pharmaceutical applications, and growing investments by key players in this market. Based on type, the global oritavancin API market can be segmented into min purity less than 98%, min purity 98%-99%, and min purity more than 99%. The min purity less than 98% segment is expected to account for the largest share of the global oritavancin API market in 2018. This segment is projected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. This growth can be attributed to factors such as increasing demand for low-purity oritavancin APIs from research institutes and small-scale pharmaceutical companies, easy availability of these APIs, and low cost as compared with high-purity APIs. Based on application, the global oritavancin API market can be divided into research applications and pharmaceutical applications. The research applications segment is projected to account for a larger share of the global oritavancin API market in 2018.
Product Definition:
Oritavancin is a vancomycin derivative antibiotic used to treat serious skin infections, including methicillin-resistant Staphylococcus aureus (MRSA). It is administered intravenously.
Min Purity Less Than 98%:
Oritavancin API is a new drug, which was patented in 2015. It's a pure form of orotavancin, which is an antibiotic used to treat bacterial infections. Oritavancin API has very low concentration compared to other APIs such as Amoxicillin/Cloxacillin and Ceftolozane/Ceftazidime.
Min Purity 98%-99%:
Min Purity 98%-99% is a special type of impurity that means the content of oleic acid in the product does not exceed 0.5%. It is used to produce high-purity oritavancin API, which has applications in pharmaceuticals and nutraceuticals industries.
The growing demand for high purity APIs from various end-use industries such as pharmaceutical.
Application Insights:
The research application segment led the global oritavancin API market in 2017 and is projected to witness significant growth over the forecast period. The increasing R&D activities pertaining to antibiotics for their use in human medicine is expected to be a major factor driving the segment growth. In addition, stringent government regulations regarding antibiotic usage in food animal production are anticipated to further drive demand for low-purity oritavancin APIs from 2018 to 2030.
Pharmaceutical was the second largest application of oritavancin APIs and accounted for 24% of total revenue share in 2017 due to high product purity levels that exceed 99%. Pills containing higher concentration of active ingredients have been found more effective than lower strength pills, so higher quality products are preferred by healthcare professionals when purchasing antibiotics from suppliers.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period owing to a rise in product demand and introduction of new products. In addition, high adoption of CMOs and R&D facilities for manufacturing drugs by small- and medium-sized enterprises is anticipated to drive regional growth over the forecast period.
Asia Pacific market was valued at USD X million in 2017 owing to presence of untapped opportunities with respect to oseltamivir phosphate analogues due to increasing COVID-19 cases globally.
Growth Factors:
- Increasing incidence of drug-resistant infections: The increasing incidence of drug-resistant infections is a major growth driver for the oritavancin API market. According to a study by the Centers for Disease Control and Prevention (CDC), antibiotic resistance is one of the world’s most pressing public health problems, and it is estimated that drug-resistant bacteria cause 2 million illnesses and 23,000 deaths in the U.S. every year. This growing problem is driving demand for oritavancin API as it offers an effective treatment option against multidrug-resistant pathogens such as MRSA (methicillin resistant Staphylococcus aureus) and VRE (vancomycin resistant Enterococcus).
- Rising prevalence of chronic diseases: The rising prevalence of chronic diseases such as diabetes, cancer, and heart disease is also contributing to the growth of the oritavancin API market. These conditions are often accompanied by bacterial infections that can be treated with oritavancin API drugs. In addition, patients with chronic diseases are more likely to require hospitalization than those without these conditions, which further boosts demand for oritavancin APIs.
- Growing number of approvals for use in pediatric patients: Oritavancin has been approved by both FDA and EMA for use in pediatric patients aged ≥6 months old weighing ≥8 kgs., making it one of few antibiotics available specifically for this
Scope Of The Report
Report Attributes
Report Details
Report Title
Oritavancin API Market Research Report
By Type
Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%
By Application
Research, Pharmaceutical
By Companies
Tecoland, VulcanChem, Jigs chemical, Alfa Chemistry, MuseChem, Wuhan Fortuna Chemical, Hangzhou Keying Chem, Shengda Pharmaceutical, Struchem, Suzhou Pharmaceutical Technology
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
220
Number of Tables & Figures
154
Customization Available
Yes, the report can be customized as per your need.
Global Oritavancin API Market Report Segments:
The global Oritavancin API market is segmented on the basis of:
Types
Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Research, Pharmaceutical
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Tecoland
- VulcanChem
- Jigs chemical
- Alfa Chemistry
- MuseChem
- Wuhan Fortuna Chemical
- Hangzhou Keying Chem
- Shengda Pharmaceutical
- Struchem
- Suzhou Pharmaceutical Technology
Highlights of The Oritavancin API Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Min Purity Less Than 98%
- Min Purity 98%-99%
- Min Purity More Than 99%
- By Application:
- Research
- Pharmaceutical
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oritavancin API Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oritavancin API is a medication used to treat infections caused by certain types of bacteria. It works by killing the bacteria.
Some of the major companies in the oritavancin api market are Tecoland, VulcanChem, Jigs chemical, Alfa Chemistry, MuseChem, Wuhan Fortuna Chemical, Hangzhou Keying Chem, Shengda Pharmaceutical, Struchem, Suzhou Pharmaceutical Technology.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Oritavancin API Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Oritavancin API Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Oritavancin API Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Oritavancin API Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Oritavancin API Market Size & Forecast, 2020-2028
4.5.1 Oritavancin API Market Size and Y-o-Y Growth
4.5.2 Oritavancin API Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Min Purity Less Than 98%
5.2.2 Min Purity 98%-99%
5.2.3 Min Purity More Than 99%
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Research
6.2.2 Pharmaceutical
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Oritavancin API Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Oritavancin API Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Min Purity Less Than 98%
9.6.2 Min Purity 98%-99%
9.6.3 Min Purity More Than 99%
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Research
9.10.2 Pharmaceutical
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Min Purity Less Than 98%
10.6.2 Min Purity 98%-99%
10.6.3 Min Purity More Than 99%
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Research
10.10.2 Pharmaceutical
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Min Purity Less Than 98%
11.6.2 Min Purity 98%-99%
11.6.3 Min Purity More Than 99%
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Research
11.10.2 Pharmaceutical
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Min Purity Less Than 98%
12.6.2 Min Purity 98%-99%
12.6.3 Min Purity More Than 99%
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Research
12.10.2 Pharmaceutical
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Min Purity Less Than 98%
13.6.2 Min Purity 98%-99%
13.6.3 Min Purity More Than 99%
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Research
13.10.2 Pharmaceutical
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Oritavancin API Market: Competitive Dashboard
14.2 Global Oritavancin API Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Tecoland
14.3.2 VulcanChem
14.3.3 Jigs chemical
14.3.4 Alfa Chemistry
14.3.5 MuseChem
14.3.6 Wuhan Fortuna Chemical
14.3.7 Hangzhou Keying Chem
14.3.8 Shengda Pharmaceutical
14.3.9 Struchem
14.3.10 Suzhou Pharmaceutical Technology
